Immuno-oncology startup Stipe has secured $22m in a round co-led by Novo Seeds, after being incubated at Novo's BioInnovation Institute.
Novo Seeds, the company creation arm of pharmaceutical company Novo, has co-led a €20m ($22m) series A round for Denmark-based immuno-oncology drug developer Stipe Therapeutics.
The round was co-led by life sciences investment firm Arix Bioscience and included Wellington Partners’ Life Science Venture Capital Management fund and Sunstone Life Science Ventures.
Spun out of Aarhus University’s Department of Biomedicine in 2018, Stipe is working on treatments for tumours and autoimmune disorders that will target the immune system’s STING (stimulator of…
